TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an Active Swallowing Rehabilitation on Quality of Life of Patients Treated by Radiotherapy for Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient treated for histologically proven head and neck cancer (oral cavity, oropharynx, or hypopharynx cancer) of stages I-IV or larynx cancer of stages II-IV, all histologic type, without distant metastasis~* Indication of curative radiotherapy alone or associated to chemotherapy or targeted therapy, without planned surgery~* WHO (World Health Organization) Performance Status 0, 1 or 2~* Sufficient cognitive capacities to complete a QoL questionnaire (evaluation by the physician at inclusion)~* Written informed consent~* Patients with health insurance~Exclusion Criteria:~* Previous radiotherapy or surgery of the upper aerodigestive tract~* Cancer of paranasal sinuses or nasopharynx or skull base~* Medical history of nervous system disease associated to significant sequelae in terms of dysphagia~* Pregnant or breast-feeding woman~* Patient under guardianship, trusteeship or judicial protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early active swallowing therapy (Type: EXPERIMENTAL): None
- Usual care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metformin in Patients With PCOS and Predictors of Poor Ovarian Response Ongoing In-vitro Fertilization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PCOS~* Prognosis for poor response~* Infertility~Exclusion Criteria:~* Male factor infertility~* Tubal infertility

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin pre-treatment and co-administration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo pre-treatment and co-administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Have a clinical diagnosis of stable patchy alopecia areata (AA) defined as no current areas of spontaneous regrowth.~2. Have a Severity of Alopecia Tool (SALT) score of at least 15% up to 95% total scalp hair loss determined by the study investigator at baseline.~3. Have a duration of the current episode of scalp hair loss of a minimum of 6 months and a maximum of 12 years.~4. If a woman of childbearing potential (WOCBP), must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2) and agree to: use a highly effective method of birth control for the duration of the study; not be planning a pregnancy during the study duration and use contraception for 30 days after last application of study medication.~Exclusion Criteria:~1. Females who are nursing, pregnant, or planning to become pregnant for the duration of the study and up to 30 days after the last application of study medication.~2. Diffuse alopecia areata.~3. Concomitant hair loss disorder (by history or physical exam) such as androgenetic alopecia or scarring alopecia (e.g., cicatricial alopecia, frontal fibrosing alopecia, etc.).~4. Active skin disease on the scalp (such as psoriasis or seborrheic dermatitis) or a history of skin disease on the scalp that in the opinion of the investigator would interfere with the study assessments of efficacy or safety.~5. Active scalp trauma or other condition affecting the scalp that, in the investigator's opinion, may affect the course of AA or interfere with the study conduct or evaluations.~6. The presence of a permanent or difficult to remove hairpiece or wig that will, in the opinion of the investigator, interfere with study assessments if not removed at each visit.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ATI-50002 high dose Topical Solution (Type: ACTIVE_COMPARATOR): High dose active
- ATI-50002 low dose Topical Solution (Type: ACTIVE_COMPARATOR): low dose active
- Vehicle Topical Solution (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Afatinib Genomic Landscape

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria/Exclusion Criteria:~* Diagnosis of metastatic stage IIIB/IV lung adenocarcinoma~* Presence of known sensitizing mutations in EGFR TK domain (exon 19 deletion and L858R)~* Absence of known resistant mutations in the EGFR TK domain (T790M)~* Consented to HRPO # 201305031 (Tissue and Blood Acquisition for Genomic Analysis and Collection of Health Information from Patients with Thoracic Malignancies, Suspected Thoracic Malignancies, or Mesothelioma)~* No prior treatment for this malignancy~* No prior localized therapy to the biopsy site~* Planned treatment with standard of care afatinib at 40 mg QD (daily)~* Not pregnant or breastfeeding~* At least 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Platelet-rich Plasma (PRP) Injection for Treating Shoulder Subacromial Impingement Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any adult male or female between 18 and 65 years of age, inclusive, with clinical diagnosis of shoulder subacromial impingement~Exclusion Criteria:~* Age below 18 or above 65 years~* History of prior shoulder injections or surgery~* History of fracture of the acromion, clavicle, scapula, or proximal humerus~* Known allergy to corticosteroids~* Known allergy to lidocaine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- platelet-rich plasma group (Type: EXPERIMENTAL): Autologous platelet-rich plasma subacromial injection
- Methylprednisolone group (Type: ACTIVE_COMPARATOR): Methylprednisolone subacromial injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically recurrent, or advanced NSCLC: Stage IV disease; or Stage IIIB due to malignant pleural effusion is allowed- only if successfully pleurodesed.~* Tumor tissue slides must express phosophorylated pdgf-rB by IHC.~* At least one measurable target lesion as defined by RECIST criteria that has not been irradiated.~* No prior chemotherapy treatment for this disease will be allowed. Patients with brain metastasis will have to be, after appropriate treatment, neurologically stable for at least 1-2 weeks (off steroids) prior to study enrollment.~* ECOG performance status 0-1.~* Meets initial laboratory parameters.~* Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.~Exclusion Criteria~* Any prior treatment with a biologic response modifier or chemotherapeutic agent for this disease.~* Any concomitant malignancy except non-melanoma skin cancer or in-situ carcinoma of the cervix.~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to STI571 and/or docetaxel, or other drugs formulated with polysorbate 80 and/or cisplatin.~* Patients with:~  * Contrast allergy.~ * GI bleed ≤ 1 month from study enrollment.~ * Intermittent or chronic oxygen requirements.~ * Pulse oximetry \<90%.~ * Grade 3 dyspnea.~ * History of poorly regulated anticoagulation with warfarin.~ * Edema or fluid retention grade \>1.~ * Neuropathy grade ≥1.~* Uncontrolled inter-current medical illness including, but not limited to, ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure, unstable angina pectoris, ≤3 months myocardial infarction or cardiac arrhythmia.~* Psychiatric illness/social situations that would limit compliance with study requirement or that would prevent informed consent or psychiatric illness/social situations requiring inpatient treatment within the past 3 months.~* Any type of hearing impairment.~* Known HIV infection.~* Receiving other investigational agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Adult patients, ≥18 years of age~* Rheumatoid arthritis for ≥ 3 months~* Inadequate clinical response to methotrexate at a dose of 7.5-25mg/week for ≥ 12 weeks~Exclusion criteria:~* Rheumatic autoimmune disease or inflammatory joint disease, other than RA~* Prior receipt of any biologic therapy for RA~* Concurrent treatment with any DMARD (other than methotrexate)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo × 2 IV + MTX (Type: PLACEBO_COMPARATOR): Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.
- Ocrelizumab 200 mg × 2 IV + MTX (Type: EXPERIMENTAL): Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
- Ocrelizumab 500 mg × 2 IV + MTX (Type: PLACEBO_COMPARATOR): Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Nanoparticles Emitted by Aircraft Engines, Impact on the Respiratory Function:

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject must be given free and informed consent and signed the consent~* Subject must be affiliated or beneficiary in a health insurance plan~* Subject included in our previous study (RBC No: 2011-A00646-35; NCT03098784)~Exclusion Criteria:~- Subject has a cons-indication (or an incompatible combination therapy) for the realization of the EFR.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Air France Company's Employees Working (Type: None): Observational cohort : Air France Company's Employees Working in the Marseilles and Paris Airports having Respiratoy health, biological investigations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Enteral Tranexamic Acid in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Critically ill patients admitted to ICU within 48 hours of onset of illness~* Patients with feeding tubes (e.g., orogastric, nasogastric, PEG, etc.)~Exclusion Criteria:~* primary admitting diagnosis of cancer~* primary admitting diagnosis of acute congestive heart failure~* primary admitting diagnosis of chronic obstructive pulmonary disease (COPD)~* primary admitting diagnosis of acute myocardial infarction or unstable cardiac arrythmia~* primary admitting diagnosis of amyotrophic lateral sclerosis (ALS) or other non-infectious disease~* primary admitting diagnosis of post-operative neurosurgical procedure~* known hypersensitivity to tranexamic acid~* acquired disturbances of color vision~* hematuria cause by disease of the renal parenchyma~* active thromboembolic disease such as deep venous thrombosis or pulmonary embolism~* patients with known clotting disorders or other known bleeding disorders~* recent (within 3 months) or active cerebrovascular bleed~* pregnancy~* inability to take study medicine (i.e., ileus with \> 500ml stomach residuals, NPO status)~* patients excluded at the discretion of the treating physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tranexamic acid (Type: EXPERIMENTAL): Study group receives enteral tranexamic acid in normal saline in addition to usual care.
- Control group (Type: PLACEBO_COMPARATOR): Control group receives vehicle (normal saline) without study drug and usual care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of the CiTop™ ExPander™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent obtained prior to any trial activities.~2. Patients, male or female between 21 and 80 years of age, with no significant co-morbidities (see exclusion criteria).~3. Patient has an angiographic documented Chronic Total Occlusion showing distal TIMI flow 0 to 1.~Exclusion Criteria:~1. Patient unable to give informed consent.~2. Current participation in another study with any investigational drug or device.~3. Factors making follow-up and/or repeat angiography difficult or unlikely.~4. Contra-indication to emergency artery by pass surgery.~5. Lack of surgical backup.~6. Contra-indication to treatment with Aspirin, or Clopidogrel and/or Heparin.~7. Lesion \> 40mm in length (both calcified lesion and adjacent thrombus).~8. Treated vessel referenced diameter less than 2.5 mm.~9. Visualization of the distal lumen less than the Rentrop Classification Grade 2 collateralization.~10. Non-visible entry point of target lesion.~11. Totally occluded bypass graft as target vessel.~12. Acute MI less than 1 week before procedure.~13. Patient has significant LV dysfunction, 35% LVEF or less.~14. Patient with cancer or other sever chronic disease with life expectance of 2 years.~15. Patient has chronic renal failure with serum creatinine ≥2.~16. Hemoglobin ≤11.~17. Patient is known or suspected not to tolerate the contrast agent.~18. Morbid Obesity (BMI \> 40).~19. Drug abuse or alcoholism.~20. Patients under custodial care.~21. Pregnant women or women with childbearing potential with a positive pregnancy test at the time of procedure.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Macular Pigment and Visual Performance in Glaucoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* glaucoma diagnosis: To be considered glaucomatous, patients will be required to have: (1) history of elevated intraocular pressure (IOP; over 21 mmHg); (2) at least two consecutive and reliable standard automated perimetry (SAP) examinations with either a pattern standard deviation (PSD) outside the 95% normal limits or a glaucoma hemifield test (GHT) result outside the 99% normal limits; and/or glaucomatous optic neuropathy.~* between the ages of 18 and 75 years,~* must be able and willing to provide signed informed consent and follow study instructions.~Exclusion Criteria:~* no systemic disease, no other ocular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lutein, zeaxanthin and mesozeaxanthin (Type: ACTIVE_COMPARATOR): Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain 22 mg total of the carotenoids lutein (10 mg), zeaxanthin (2 mg), and mesozeaxanthin (10 mg).
- Placebo (Type: PLACEBO_COMPARATOR): Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain only sunflower oil (placebo).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Validation of 18F-MISO-PET and 18F-FLT-PET

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stage II-IV squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, planned for curative resection.~* Age \>18 years.~* Written informed consent.~Exclusion Criteria:~* Pregnancy.~* Prior treatment for this tumor~* Women breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Severe Head Trauma: Coagulation and CT-Scan Aggravation.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults~* Patients informed and did not object to the collection of their medical data for the study~* Patient admitted in Trauma center between January 2016 and December 2018 severe head injury defined by a Glasgow Coma Scale (GCS) \< 9 AND/OR Abnormalities on the first brain CT-scan with pathological transcranial Doppler (Vd \< 25 cm/s and IP \> 1.25)~Exclusion Criteria:~* Abbreviated Injury Score (AIS) head and neck ≤ 3 AND/OR AIS out of head and neck \> 3~* Taking drugs that interfere with hemostasis, such as anticoagulant or antiplatelet antiaggregants in preventive or curative doses;~* Patients under guardianship~* Patients still alive at the time of data collection AND opposed to the collection of their data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female patient who has a locally advanced or metastatic breast cancer~* Indication of Halaven treatment :~patient pretreated with anthracyclines or taxanes, patient who has received at least 1 chemotherapy regimen for their advanced or metastatic stage~* Patient who has had enough time to have retrieved her hair or whose last chemotherapy regimen didn't induce alopecia.~* Aged ≥ 18 years~* Non-opposition of the patient must have been collected~Exclusion Criteria:~* Skin metastasis of the scalp~* Sensitivity to cold, cold agglutinin disease or cryoglobulinemia~* Impossibility to submit at the study procedures due to geographic, social or mental reasons

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues